Zürich BioGenix
PT-141 · 10mg
PT-141 · 10mg
Couldn't load pickup availability
✓ HPLC Purity >99% ✓ COA on Every Batch ✓ Cold Chain Maintained ✓ EU Compliant
PT-141 (Bremelanotide) is a cyclic synthetic melanocortin peptide derived from Melanotan-II that acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, and MC4R. Unlike PDE5 inhibitors, PT-141 operates centrally via MC4R activation in the CNS, making it a subject of significant research interest in the neurobiology of sexual function, motivation pathways, and melanocortin system pharmacology.
Synthesised and lyophilised in Zürich to >99% HPLC purity. Lot-traceable with full COA available upon request.
Technical Specifications
| Chemical Name | PT-141 (Bremelanotide) |
| CAS Number | 189691-06-3 |
| Molecular Formula | C50H68N14O10 |
| Molecular Weight | 1025.17 g/mol |
| Receptor Targets | MC1R, MC3R, MC4R (melanocortin receptors) |
| Purity | >99% (HPLC-UV) |
| Form | Lyophilised Powder |
| Storage | -20C, protect from light and moisture |
| Reconstitution | Bacteriostatic water or sterile saline |
Research & Literature
PT-141 (Bremelanotide) was developed from Melanotan-II and is the first melanocortin-based drug to receive FDA approval (as Vyleesi) for hypoactive sexual desire disorder. Research by Molinoff et al. and others has characterised its mechanism of action at CNS melanocortin receptors, particularly MC4R, which mediates sexual arousal independently of vascular pathways. Studies have also explored its potential in neuroprotection and metabolic regulation.
For research purposes only. Not for human consumption. Supplied in accordance with EU Regulation (EC) No 1907/2006 (REACH) for research and analytical use.
Share
